These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19116277)

  • 1. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
    Artis DR; Lin JJ; Zhang C; Wang W; Mehra U; Perreault M; Erbe D; Krupka HI; England BP; Arnold J; Plotnikov AN; Marimuthu A; Nguyen H; Will S; Signaevsky M; Kral J; Cantwell J; Settachatgull C; Yan DS; Fong D; Oh A; Shi S; Womack P; Powell B; Habets G; West BL; Zhang KY; Milburn MV; Vlasuk GP; Hirth KP; Nolop K; Bollag G; Ibrahim PN; Tobin JF
    Proc Natl Acad Sci U S A; 2009 Jan; 106(1):262-7. PubMed ID: 19116277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.
    Berger J; Leibowitz MD; Doebber TW; Elbrecht A; Zhang B; Zhou G; Biswas C; Cullinan CA; Hayes NS; Li Y; Tanen M; Ventre J; Wu MS; Berger GD; Mosley R; Marquis R; Santini C; Sahoo SP; Tolman RL; Smith RG; Moller DE
    J Biol Chem; 1999 Mar; 274(10):6718-25. PubMed ID: 10037770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors.
    Fang F; Kang Z; Wong C
    Mol Nutr Food Res; 2010 Mar; 54(3):345-52. PubMed ID: 19866471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic effects of chamomile flowers extract in obese mice through transcriptional stimulation of nutrient sensors of the peroxisome proliferator-activated receptor (PPAR) family.
    Weidner C; Wowro SJ; Rousseau M; Freiwald A; Kodelja V; Abdel-Aziz H; Kelber O; Sauer S
    PLoS One; 2013; 8(11):e80335. PubMed ID: 24265809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.
    Christensen KB; Minet A; Svenstrup H; Grevsen K; Zhang H; Schrader E; Rimbach G; Wein S; Wolffram S; Kristiansen K; Christensen LP
    Phytother Res; 2009 Sep; 23(9):1316-25. PubMed ID: 19172665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    Gani OA
    Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation effects of TZQ-F on adipocyte differentiation and insulin action.
    Nan Xia J; Qin Zhang D; Du J; Wen J
    J Ethnopharmacol; 2013 Nov; 150(2):692-9. PubMed ID: 24095827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypharmacology of N
    Yu J; Ahn S; Kim HJ; Lee M; Ahn S; Kim J; Jin SH; Lee E; Kim G; Cheong JH; Jacobson KA; Jeong LS; Noh M
    J Med Chem; 2017 Sep; 60(17):7459-7475. PubMed ID: 28799755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
    Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
    J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
    Huang F; Zeng Z; Zhang W; Yan Z; Chen J; Yu L; Yang Q; Li Y; Yu H; Chen J; Wu C; Zhang XK; Su Y; Zhou H
    Eur J Med Chem; 2021 Oct; 222():113542. PubMed ID: 34118723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.